Effect of timing of amantadine chemoprophylaxis on severity of outbreaks of influenza A in adult long-term care facilities

Clinical Infectious Diseases

Volumn 47, Issue 1, 2008, Pages 47-52

  Rubin, Marcie S ^a   Nivin, Beth ^b   Ackelsberg, Joel ^b  

^a Columbia University ^*  (United States)

^b NEW YORK STATE DEPARTMENT OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIVIRUS AGENT;

ADULT; ARTICLE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; EPIDEMIC; FATALITY; HEALTH CARE FACILITY; HUMAN; INFLUENZA; INFLUENZA VIRUS A; LONG TERM CARE; MAJOR CLINICAL STUDY; MORBIDITY; PRIORITY JOURNAL; CROSS INFECTION; INCIDENCE; MORTALITY; MULTIVARIATE ANALYSIS; STATISTICAL MODEL; TIME; UNITED STATES;

ADULT; AMANTADINE; ANTIVIRAL AGENTS; CHEMOPREVENTION; CROSS INFECTION; DISEASE OUTBREAKS; HEALTH FACILITIES; HUMANS; INCIDENCE; INFLUENZA, HUMAN; LINEAR MODELS; LONG-TERM CARE; MULTIVARIATE ANALYSIS; NEW YORK; TIME FACTORS;

EID: 46249105017     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/588658     Document Type: Article

References (25)

1. Nichol KL, Nordin J, Mullooly J, Lask R, Fillbrandt K, Iwane M. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med 2003; 348:1322-32.
2. Bridges CB, Kuehnert MJ, Hall CB. Transmission of influenza: implications for control in health care settings. Clin Infect Dis 2003; 37:1094-101.
3. Gravenstein S, Davidson HE. Current strategies for management of influenza in the elderly population. Clin Infect Dis 2002; 35:729-37.
4. Goodman RA, Orenstein WA, Munro TF, Smith SC, Sikes RK. Impact of influenza A in a nursing home. JAMA 1982; 247:1451-3.
5. Harper SA, Fukuda K, Uyeki TM, Cox NJ, Bridges CB. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2004; 53:1-40.
6. Patriarca PA, Weber JA, Parker RA, et al. Efficacy of influenza vaccine in nursing homes: reduction in illness and complications during an influenza A (H3N2) epidemic. JAMA 1985; 253:1136-9.
7. Arden NH, Patriarca PA, Fasano MB, et al. The roles of vaccination and amantadine prophylaxis in controlling an outbreak of influenza A (H3N2) in a nursing home. Arch Intern Med 1988; 148:865-8.
8. Atkinson WL, Arden NH, Patriarca PA, Leslie N, Lui KJ, Gohd R. Amantadine prophylaxis during an institutional outbreak of type A (H1N1) influenza. Arch Intern Med 1986; 146:1751-6.
9. Peters NL, Oboler S, Hair C, Laxson L, Kost J, Meiklejohn G. Treatment of an influenza A outbreak in a teaching nursing home: effectiveness of a protocol for prevention and control. J Am Geriatr Soc 1989; 37:210-8.
10. Centers for Disease Control and Prevention. Control of influenza A outbreaks in nursing homes: amantadine as adjunct to vaccine: 1989-1990. JAMA 1992; 267:344-6.
11. Staynor K, Foster G, McArthur M, McGeer A, Petric M, Simor AE. Influenza A outbreak in a nursing home: the value of early diagnosis and the use of amantadine hydrochloride. Can J Infect Control 1994;9:109-11.
12. Ambrozaitis A, Gravenstein S, van Essen GA, et al. Inhaled zanamivir versus placebo for the prevention of influenza outbreaks in an unvaccinated long-term care population. J Am Med Dir Assoc 2005; 6:367-74.
13. Monto AS, Rotthoff J, Teich E, et al. Detection and control of influenza outbreaks in well-vaccinated nursing home populations. Clin Infect Dis 2004; 39:459-64.
14. Bush KA, McAnulty J, McPhie K, et al. Antiviral prophylaxis in the management of an influenza outbreak in an aged care facility. Commun Dis Intell 2004; 28:396-400.
15. Bowles SK, Lee W, Simor AE, et al. Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999-2000. J Am Geriatr Soc 2002; 50:608-16.
16. Gravenstein S, Drinka P, Osterweil D, et al. Inhaled zanamivir versus rimantadine for the control of influenza in a highly vaccinated long-term care population. J Am Med Dir Assoc 2005; 6:359-66.
17. McKimm-Breschkin JL. Management of influenza virus infections with neuraminidase inhibitors : detection, incidence, and implications of drug resistance. Treat Respir Med 2005; 4:107-16.
18. Lee C, Loeb M, Phillips A, et al. Zanamivir use during transmission of amantadine-resistant influenza A in a nursing home. Infect Control Hosp Epidemiol 2000; 21:700-4.
19. Schilling M, Povinelli L, Krause P, et al. Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks. Vaccine 1998; 16:1771-4.
20. New York State Department of Health. Health care facility infection control (nosocomial) report. Available at: http://www.health.state.ny.us/nysdoh/ infection/infecreport.pdf. Accessed 2 November 2007.
21. Fox J. Regression diagnostics. Quantitative applications in the social sciences series no. 79. Thousand Oaks, CA: Sage Publications; 1991.
22. Centers for Disease Control and Prevention. 2001-2002 Influenza season summary. 10 June 2002. Available at: http://www.cdc.gov/flu/weekly/ weeklyarchives2001-2002/01-02summary.htm. Accessed 24 December 2007.
23. Centers for Disease Control and Prevention. 2002-2003 Influenza season summary. 3 July 2003. Available at: http://www.cdc.gov/flu/weekly/ weeklyarchives2002-2003/02-03summary.htm. Accessed 24 December 2007.
24. Centers for Disease Control and Prevention. 2003-2004 Influenza season summary. 29 June 2004. Available at: http://www.cdc.gov/flu/weekly/ weeklyarchives2003-2004/03-04summary.htm. Accessed 24 December 2007.
25. Centers for Disease Control and Prevention. CDC recommends against the use of amantadine and rimantadine for the treatment or prophylaxis of influenza in the United States during the 2005-06 influenza season. CDC Health Alert. 14 January 2006.